A Systematic Comparative Literature Review of Biomarkers, Imaging, and Therapeutic Strategies for Endometrial Cancer: Toward an Estrogen Receptor-Guided Near-Infrared Fluorescence Imaging and Endocrine Therapy Pipeline

In the developed world, a specific type of cancer affecting the lining of the uterus has become the most common gynecologic malignancy. Its numbers are rising, driven by an aging population and increasing rates of obesity. For decades, the path to treating this disease has been a slow, invasive, and anxiety-inducing process. When a woman experiences abnormal bleeding, doctors must perform a procedure to remove a small piece of tissue from the uterus. This tissue is then sent to a laboratory, where it is sliced, stained, and examined under a microscope by a pathologist. This entire sequence, from the initial procedure to the final diagnosis and the start of treatment, typically takes between ten and fifteen days. During this waiting period, patients endure significant psychological distress, and the medical system incurs high costs and procedural risks, such as infection or injury to the organ.

The core challenge lies in the fact that the most common form of this cancer is driven by a specific protein called the estrogen receptor. When this protein is present, the cancer cells respond well to hormone-blocking drugs, known as endocrine therapy. However, confirming whether a patient has this protein currently requires the slow, invasive biopsy and lab work described above. Researchers have long sought a way to detect this protein directly inside the body, in real time, without the need to wait for a lab report. If doctors could see the presence of this protein during the initial examination, they could potentially skip the waiting period and begin the correct treatment almost immediately.

A new systematic review published in September 2026 by Kinzy Wessam Mohamed Ali and Stem Behera tackles this exact problem. The author did not conduct a new experiment on patients; instead, they gathered and analyzed a vast collection of existing scientific studies, clinical guidelines, and trial data from 2013 to 2026. Their goal was to act as a strategic planner, comparing different biological markers, imaging tools, and treatment options to find the single best combination for a faster, less invasive diagnostic system. They treated the search for a solution like a complex puzzle, weighing the pros and cons of every available piece of evidence to see which ones fit together best.

The author began by looking at five different biological markers that could potentially identify the cancer. These included the estrogen receptor, a related protein called the progesterone receptor, and three other markers often used in ovarian cancer or for detecting specific genetic mutations. They scored each one based on how common it is in the most frequent type of uterine cancer, how clearly it points to a specific treatment, how safe and mature the testing methods are, and how easy it is to access. The estrogen receptor emerged as the clear winner. It is present in the vast majority of the most common, less aggressive tumors, and its presence directly tells doctors that hormone-blocking drugs will work. The other markers, while useful in specific situations, did not offer the same broad, direct link to a simple, effective treatment for the majority of patients.

Next, the team evaluated four different ways to detect these markers inside the body without waiting for a lab. The options ranged from standard radiation-based scans to new methods using liquid blood samples and tiny electronic sensors. The review focused heavily on a technique called near-infrared fluorescence endoscopy. This method involves using a special camera and a harmless, glowing dye that can be seen with the naked eye through a scope inserted into the uterus. The author found this approach to be the most promising because it can be done during the same procedure where the doctor looks inside the uterus, it does not expose the patient to radiation, and it fits into the equipment already found in most gynecology clinics. While the technology for seeing the glow is ready, the specific "glowing dye" that targets the estrogen receptor protein needs to be developed and tested, but the platform to use it is already in place.

Finally, the researchers matched these findings with the available treatments. They compared hormone-blocking drugs against newer immunotherapy drugs. Because the winning biomarker was the estrogen receptor, the winning treatment was naturally the hormone-blocking therapy. This combination creates a logical, seamless path: detect the protein, and immediately treat with the drug that stops it. The author then synthesized these three choices—the estrogen receptor, the glowing camera, and the hormone drugs—into a proposed new workflow. In this hypothetical scenario, a patient would arrive with symptoms, undergo a quick examination with the special camera, and receive a result within hours. If the camera detects the protein, the patient could start the hormone therapy within forty-eight hours, cutting the current two-week wait down to less than two days.

The review is careful to clarify that this streamlined pipeline is a proposal based on existing evidence, not a finished medical product. The author explicitly states that the specific glowing probe needed to see the estrogen receptor has not yet been fully developed or tested in humans for this purpose. They acknowledge that before this system can be used in a hospital, scientists must build the probe, prove it is safe, and run large clinical trials to show it works as well as the current lab tests. However, the study provides a clear, evidence-based roadmap for how such a system could be built. By systematically comparing every option, the author has identified that the most effective way to speed up care for the majority of patients is to focus on the estrogen receptor, use a camera-based imaging technique, and pair it with hormone therapy. This approach promises to transform a weeks-long ordeal into a same-day event, offering a future where the delay between diagnosis and treatment is a thing of the past.